Business
10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases
Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc.
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People \nPLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today its involvement in TenK10K, a large-scale, multi-year study led by the Garvan Institute of Medical Research. The TenK10K project intends to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer. For this groundbreaking project, the Garvan Institute selected Chromium GEM-X products to generate single cell data to improve the accuracy of predicting disease risk and treatment response.\n\n \n \n \n \n \n \n\n \n\"TenK10K has the potential to enable a significant step forward in personalized medicine,\" said Professor Joseph Powell, leader of the TenK10K project, Program Director for Translational Genomics at the Garvan Institute of Medical Research, and Director of the UNSW Cellular Genomics Futures Institute. \"Through single cell sequencing, which analyzes individual cells rather than an average of many cells, we can see fingerprints that we've never been able to distinguish. We are excited by translational opportunities that come from combining these leading sequencing and single cell technologies with advanced machine learning methods.\"\nOne of the largest projects of its kind, TenK10K aims to improve how accurately disease-linked immune cell fingerprints can be identified and develop:\nCommercial tests to identify the right therapy for challenging autoimmune diseases including multiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease and Crohn's diseaseEarly trials of powerful new RNA therapiesPotential early targets for treatments for cancers and long COVIDTests to track the aftermath of heart attacks and identify risk of sudden deathAs part of this new study, the Garvan Institute will use Chromium GEM-X products, the next generation of 10x Genomics' leading single cell technology, delivering increased sensitivity, throughput, data quality and sample recovery. GEM-X is uniquely positioned for translational research, delivering class-leading performance at larger scale and lower cost, even with more challenging samples.\n\"Single cell analysis at a massive scale has t...